TY - JOUR
T1 - Synthesis and SAR exploration of dinapsoline analogues
AU - Sit, Sing Yuen
AU - Xie, Kai
AU - Jacutin-Porte, Swanee
AU - Boy, Kenneth M.
AU - Seanz, James
AU - Taber, Matthew T.
AU - Gulwadi, Amit G.
AU - Korpinen, Carolyn D.
AU - Burris, Kevin D.
AU - Molski, Thaddeus F.
AU - Ryan, Elaine
AU - Xu, Cen
AU - Verdoorn, Todd
AU - Johnson, Graham
AU - Nichols, David E.
AU - Mailman, Richard B.
N1 - Funding Information:
Microanalyses, X-ray analyses, IR spectra, and mass spectra were kindly provided for by the Bristol-Myers Squibb Department of Analytical Research and Development. This work resulted in part from the support of NIH grants MH40537, MH42705, and NS39036.
PY - 2004/2/15
Y1 - 2004/2/15
N2 - Dinapsoline is a full D1 dopamine receptor agonist that produces robust rotational activity in the unilateral 6-OHDA rat model. This compound is orally active, and shows a low tendency to cause tolerance in rat models. The active enantiomer was determined to have the S-(+) configuration, and the opposite enantiomer is essentially devoid of biological activity. Taken together, dinapsoline has significant metabolic and pharmacological advantages over previous D1 agonists. In an attempt to define the structure-activity relationships (SARs) and to map out the key elements surrounding the unique structure of dinapsoline, core analogues and substitution analogues of the parent tetracyclic condensed ring structure were prepared. Based on a recently developed synthesis of dinapsoline and its enantiomers, both core and substitution analogues on all four rings (A, B′, C and D ring) of dinapsoline were synthesized. It was found that affinity for both D1and D2 receptors was decreased by most substituents on the A, B′, and C rings, whereas D ring substitutions preserved much of the dopamine receptor binding activity.
AB - Dinapsoline is a full D1 dopamine receptor agonist that produces robust rotational activity in the unilateral 6-OHDA rat model. This compound is orally active, and shows a low tendency to cause tolerance in rat models. The active enantiomer was determined to have the S-(+) configuration, and the opposite enantiomer is essentially devoid of biological activity. Taken together, dinapsoline has significant metabolic and pharmacological advantages over previous D1 agonists. In an attempt to define the structure-activity relationships (SARs) and to map out the key elements surrounding the unique structure of dinapsoline, core analogues and substitution analogues of the parent tetracyclic condensed ring structure were prepared. Based on a recently developed synthesis of dinapsoline and its enantiomers, both core and substitution analogues on all four rings (A, B′, C and D ring) of dinapsoline were synthesized. It was found that affinity for both D1and D2 receptors was decreased by most substituents on the A, B′, and C rings, whereas D ring substitutions preserved much of the dopamine receptor binding activity.
UR - http://www.scopus.com/inward/record.url?scp=0842265855&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0842265855&partnerID=8YFLogxK
U2 - 10.1016/j.bmc.2003.11.015
DO - 10.1016/j.bmc.2003.11.015
M3 - Article
C2 - 14759732
AN - SCOPUS:0842265855
SN - 0968-0896
VL - 12
SP - 715
EP - 734
JO - Bioorganic and Medicinal Chemistry
JF - Bioorganic and Medicinal Chemistry
IS - 4
ER -